Alto Neuroscience, Inc.
HealthcareNYSE:ANRO · New York Stock Exchange
+$0.04 today
Vol 0.24M · Avg 0.35M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-41.8%
avg 22.8%
ROIC
-38.2%
avg -46.8%
ROA
-34.2%
avg -39.4%
Analysis
ROA is currently the strongest return metric at -34.2% versus its period average of -39.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Amit Etkin | Founder, Chairman of the Board, Chief Executive Officer & President | $1.25M | — | 49 | $833,949.00 | 2.38% |
Nicholas C. Smith | Chief Financial Officer & Chief Business Officer | $946,862.00 | — | 37 | $24,060.00 | 0.07% |
Michael C. Hanley | Chief Operating Officer | $695,330.00 | — | 52 | $131,000.00 | 0.37% |
Adam Savitz | Chief Medical Officer | $579,569.00 | — | 60 | $124,000.00 | 0.35% |
Erin R. McQuade | General Counsel, Chief Administrative Officer & Corporate Secretary | — | — | 51 | — | — |
Dan Segal | Co-Founder & Strategic Advisor | — | — | 64 | — | — |
Jessica Powell | Chief Development Officer | — | — | 51 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$889.71M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$444.15M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Silence Therapeutics plc
NASDAQ:SLN
$316.00M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
Cellectis S.A.
NASDAQ:CLLS
$310.29M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$296.96M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$106.17M
Who manages ANRO?
Alto Neuroscience, Inc. (ANRO) lists 7 active executives. The top listed executive is Erin R. McQuade, General Counsel, Chief Administrative Officer & Corporate Secretary.
Are ANRO insiders buying or selling?
Recent insider activity shows net buying of $8.01M.
Explore More
Continue the stock analysis
Jump to another research area for this company.